JP2020517700A - Ｓｔｉｎｇアゴニストを含む抗体コンジュゲート - Google Patents
Ｓｔｉｎｇアゴニストを含む抗体コンジュゲート Download PDFInfo
- Publication number
- JP2020517700A JP2020517700A JP2019558397A JP2019558397A JP2020517700A JP 2020517700 A JP2020517700 A JP 2020517700A JP 2019558397 A JP2019558397 A JP 2019558397A JP 2019558397 A JP2019558397 A JP 2019558397A JP 2020517700 A JP2020517700 A JP 2020517700A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkenyl
- alkynyl
- phenyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762491879P | 2017-04-28 | 2017-04-28 | |
| US62/491,879 | 2017-04-28 | ||
| PCT/US2018/029570 WO2018200812A1 (en) | 2017-04-28 | 2018-04-26 | Antibody conjugates comprising sting agonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517700A true JP2020517700A (ja) | 2020-06-18 |
| JP2020517700A5 JP2020517700A5 (https=) | 2021-06-10 |
Family
ID=62165655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019558397A Pending JP2020517700A (ja) | 2017-04-28 | 2018-04-26 | Ｓｔｉｎｇアゴニストを含む抗体コンジュゲート |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3615080A1 (https=) |
| JP (1) | JP2020517700A (https=) |
| CN (1) | CN110799218A (https=) |
| AR (1) | AR113224A1 (https=) |
| WO (1) | WO2018200812A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021532172A (ja) * | 2018-07-10 | 2021-11-25 | スペロヴィー バイオサイエンシズ，インコーポレーテッド | 疾患を治療するための化合物、組成物及び方法 |
| JP2024523453A (ja) * | 2021-06-25 | 2024-06-28 | ボルト バイオセラピューティクス、インコーポレーテッド | ビス－ベンゾイミダゾールｓｔｉｎｇアゴニスト免疫複合体及びその使用 |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016359235B2 (en) | 2015-11-25 | 2022-09-15 | Ligachem Biosciences Inc. | Antibody-drug conjugates comprising branched linkers and methods related thereto |
| PE20210255A1 (es) | 2016-12-01 | 2021-02-10 | Takeda Pharmaceuticals Co | Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon) |
| CA3058360A1 (en) | 2017-03-29 | 2018-10-04 | Legochem Biosciences, Inc. | Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same |
| US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| KR20200098511A (ko) | 2017-11-10 | 2020-08-20 | 다케다 야쿠힌 고교 가부시키가이샤 | Sting 조절제 화합물, 및 제조 및 사용 방법 |
| EP3505188A1 (en) * | 2017-12-29 | 2019-07-03 | Invivogen | Pro-cyclic dinucleotide conjugates for cytokine induction |
| CN112601555A (zh) | 2018-05-09 | 2021-04-02 | 乐高化学生物科学股份有限公司 | 与抗cd19抗体药物结合物相关的组合物和方法 |
| BR112020024605A2 (pt) * | 2018-06-01 | 2021-04-06 | Eisai R&D Management Co., Ltd. | Métodos para o tratamento de câncer de bexiga |
| WO2020092617A1 (en) * | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody conjugates comprising sting agonists |
| WO2020089815A1 (en) * | 2018-10-31 | 2020-05-07 | Novartis Ag | Antibody conjugates comprising sting agonist |
| KR20210107731A (ko) * | 2018-12-21 | 2021-09-01 | 노파르티스 아게 | Pmel17에 대한 항체 및 이의 접합체 |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| WO2020227421A1 (en) | 2019-05-09 | 2020-11-12 | Aligos Therapeutics, Inc. | Modified cyclic dinucleoside compounds as sting modulators |
| IL287938B2 (en) * | 2019-05-10 | 2025-07-01 | Takeda Pharmaceuticals Co | Antibody-drug conjugates |
| KR20220024106A (ko) | 2019-05-20 | 2022-03-03 | 노파르티스 아게 | Mcl-1 억제제 항체-약물 접합체 및 사용 방법 |
| JP7706210B2 (ja) | 2019-06-10 | 2025-07-11 | ストロ バイオファーマ インコーポレーテッド | ５Ｈ－ピロロ［３，２－ｄ］ピリミジン－２，４－ジアミノ化合物およびその抗体コンジュゲート |
| US20220267281A1 (en) * | 2019-06-12 | 2022-08-25 | Ontario Institute For Cancer Research (Oicr) | Unsaturated heterocycloalkyl and heteroaromatic acyl hydrazone linkers, methods and uses thereof |
| CA3147890A1 (en) * | 2019-07-19 | 2021-01-28 | Immunesensor Therapeutics, Inc. | Antibody-sting agonist conjugates and their use in immunotherapy |
| JP7843695B2 (ja) | 2019-08-02 | 2026-04-10 | メルサナ セラピューティクス インコーポレイテッド | がんの処置用のＳＴＩＮＧ（インターフェロン遺伝子刺激因子）アゴニストとしてのビス－［Ｎ－（（５－カルバモイル）－１Ｈ－ベンゾ［ｄ］イミダゾール－２－イル）－ピラゾール－５－カルボキサミド］誘導体および関連化合物 |
| CN115003383B (zh) * | 2019-08-21 | 2024-10-01 | 斯克里普斯研究学院 | 干扰素基因刺激物sting的双环激动剂 |
| KR20210028544A (ko) * | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
| WO2021046426A1 (en) * | 2019-09-06 | 2021-03-11 | Sperovie Biosciences, Inc. | Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies |
| EP4088739A4 (en) * | 2019-12-23 | 2024-11-13 | Eisai R&D Management Co., Ltd. | PROCESS FOR PRODUCING ANTIBODY-DRUG CONJUGATE BASED ON ERIBULIN |
| IL296124A (en) * | 2020-03-06 | 2022-11-01 | Daiichi Sankyo Co Ltd | Antibody-drug conjugate including novel cyclic dinucleotide derivative |
| BR112022019532A2 (pt) * | 2020-03-31 | 2022-12-06 | Orum Therapeutics Inc | Conjugados de neodegrader |
| IL296901A (en) * | 2020-04-02 | 2022-12-01 | Mersana Therapeutics Inc | Antibody-drug conjugates comprising sting agonists |
| TW202200136A (zh) | 2020-04-10 | 2022-01-01 | 日商小野藥品工業股份有限公司 | 癌治療方法 |
| US20230149560A1 (en) | 2020-04-20 | 2023-05-18 | Massachusetts Institute Of Technology | Lipid compositions for delivery of sting agonist compounds and uses thereof |
| MX2022014110A (es) | 2020-05-15 | 2023-01-30 | Immunesensor Therapeutics Inc | Tratamientos combinados de agonistas de sting con inhibidores de puntos de control inmunitario. |
| CN111592570B (zh) * | 2020-05-15 | 2022-04-29 | 清华大学 | 新型sting激动剂及其制备方法和应用 |
| IL302390A (en) | 2020-11-09 | 2023-06-01 | Takeda Pharmaceuticals Co | Drug antibody conjugates |
| US20240209080A1 (en) | 2021-04-10 | 2024-06-27 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
| JP2024514707A (ja) | 2021-04-20 | 2024-04-02 | アンスティテュ・クリー | 免疫療法における使用のための組成物及び方法 |
| CA3216459A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| JP2024526874A (ja) | 2021-07-23 | 2024-07-19 | イミューンセンサー セラピューティクス、インコーポレイテッド | サイトカインとのｓｔｉｎｇアゴニスト併用療法 |
| CN118524854A (zh) * | 2021-12-17 | 2024-08-20 | 北京加科思新药研发有限公司 | 包含可用作sting激动剂的新型化合物的化合物-连接基构建体及其用途 |
| CN115060902B (zh) * | 2022-05-13 | 2025-07-11 | 上海市第十人民医院 | 可作为肿瘤诊断和预后分析标志物的cGAS甲基化修饰及其检测试剂和应用 |
| CN120239705A (zh) | 2022-07-21 | 2025-07-01 | 萤火虫生物股份有限公司 | 糖皮质激素受体激动剂和其缀合物 |
| TW202432101A (zh) * | 2022-11-08 | 2024-08-16 | 韓商瑞嘉化學生物科學股份有限公司 | Sting促效劑 |
| TW202434307A (zh) * | 2023-01-18 | 2024-09-01 | 大陸商泰勵生物科技（上海）有限公司 | 抗體偶聯藥物及其用途 |
| AU2024234194A1 (en) | 2023-03-10 | 2025-08-07 | Novartis Ag | Panras inhibitor antibody-drug conjugates and methods of use thereof |
| GB202304385D0 (en) | 2023-03-24 | 2023-05-10 | Prostate Cancer Res | Combinatorial IL-15 therapy |
| AR133955A1 (es) | 2023-09-26 | 2025-11-19 | Profoundbio Us Co | Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos |
| CN120204418A (zh) * | 2023-12-27 | 2025-06-27 | 上海迪诺医药科技有限公司 | 环状二核苷酸化合物、其偶联物及应用 |
| WO2025149661A1 (en) | 2024-01-10 | 2025-07-17 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| US20250381289A1 (en) | 2024-02-29 | 2025-12-18 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| WO2025233676A1 (en) * | 2024-05-08 | 2025-11-13 | Ligachem Biosciences Inc. | Compositions and methods related to a combination therapy of sting agonists and immune checkpoint inhibitors |
| WO2025233679A1 (en) * | 2024-05-08 | 2025-11-13 | Ligachem Biosciences Inc. | Compositions and methods related to a combination therapy of sting agonists and antibody drug conjugates |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016511637A (ja) * | 2013-02-08 | 2016-04-21 | アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ | イムノコンジュゲートを調製する修飾抗体のための特定部位 |
| JP2016520085A (ja) * | 2013-05-18 | 2016-07-11 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法 |
| WO2016145102A1 (en) * | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene" -dependent signalling |
| WO2017019896A1 (en) * | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US8076303B2 (en) | 2005-12-13 | 2011-12-13 | Spring Bank Pharmaceuticals, Inc. | Nucleotide and oligonucleotide prodrugs |
| NZ610239A (en) | 2008-04-30 | 2014-11-28 | Immunogen Inc | Cross-linkers and their uses |
| ES2732574T3 (es) | 2012-11-30 | 2019-11-25 | Novartis Ag | Métodos para preparar conjugados a partir de proteínas que contienen disulfuro |
| US9695212B2 (en) | 2012-12-13 | 2017-07-04 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| US9840533B2 (en) | 2013-04-29 | 2017-12-12 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| WO2015074145A1 (en) | 2013-11-22 | 2015-05-28 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
| US9315523B2 (en) | 2013-12-06 | 2016-04-19 | Rutgers, The State University Of New Jersey | Cyclic dinucleosides |
| CR20160564A (es) | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| EP3546473B1 (en) | 2014-12-16 | 2025-12-10 | Kayla Therapeutics | Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction |
| WO2016161372A1 (en) * | 2015-04-01 | 2016-10-06 | President And Fellows Of Harvard College | Immunoconjugates for programming or reprogramming of cells |
| EP3317290A4 (en) | 2015-07-02 | 2019-04-10 | Spring Bank Pharmaceuticals, Inc. | COMPOSITIONS AND METHOD FOR TREATING VIRUS INFECTION |
| TW201717968A (zh) | 2015-07-14 | 2017-06-01 | 春季銀行製藥公司 | 誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物 |
| KR102222186B1 (ko) | 2015-08-13 | 2021-03-03 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
| DE212016000029U1 (de) * | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
| CN106540256A (zh) * | 2016-03-27 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用 |
| WO2018009652A1 (en) | 2016-07-06 | 2018-01-11 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| IL264049B2 (en) | 2016-07-06 | 2023-11-01 | Sperovie Biosciences Inc | Compounds, preparations and methods for treating the disease |
| WO2018013887A1 (en) | 2016-07-15 | 2018-01-18 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| CN109715202A (zh) | 2016-07-15 | 2019-05-03 | 斯必乐维生物科学公司 | 用于治疗疾病的化合物、组合物和方法 |
-
2018
- 2018-04-25 AR ARP180101063A patent/AR113224A1/es unknown
- 2018-04-26 CN CN201880043438.4A patent/CN110799218A/zh active Pending
- 2018-04-26 EP EP18724677.2A patent/EP3615080A1/en not_active Withdrawn
- 2018-04-26 JP JP2019558397A patent/JP2020517700A/ja active Pending
- 2018-04-26 WO PCT/US2018/029570 patent/WO2018200812A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016511637A (ja) * | 2013-02-08 | 2016-04-21 | アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ | イムノコンジュゲートを調製する修飾抗体のための特定部位 |
| JP2016520085A (ja) * | 2013-05-18 | 2016-07-11 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法 |
| WO2016145102A1 (en) * | 2015-03-10 | 2016-09-15 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene" -dependent signalling |
| WO2017019896A1 (en) * | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021532172A (ja) * | 2018-07-10 | 2021-11-25 | スペロヴィー バイオサイエンシズ，インコーポレーテッド | 疾患を治療するための化合物、組成物及び方法 |
| JP2024523453A (ja) * | 2021-06-25 | 2024-06-28 | ボルト バイオセラピューティクス、インコーポレーテッド | ビス－ベンゾイミダゾールｓｔｉｎｇアゴニスト免疫複合体及びその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110799218A (zh) | 2020-02-14 |
| WO2018200812A1 (en) | 2018-11-01 |
| AR113224A1 (es) | 2020-02-19 |
| EP3615080A1 (en) | 2020-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020517700A (ja) | Ｓｔｉｎｇアゴニストを含む抗体コンジュゲート | |
| JP7774025B2 (ja) | 抗体－サイトカイングラフト化タンパク質及び癌の治療における使用方法 | |
| US20210346387A1 (en) | Antibody conjugates comprising toll-like receptor agonist | |
| US20210170043A1 (en) | Dc-sign antibody conjugates comprising sting agonists | |
| US20200164084A1 (en) | Antibody conjugates comprising toll-like receptor agonist and combination therapies | |
| US20230332104A1 (en) | Zbtb32 inhibitors and uses thereof | |
| US20230053449A1 (en) | Dc-sign antibody drug conjugates | |
| WO2020089815A1 (en) | Antibody conjugates comprising sting agonist | |
| WO2021211984A1 (en) | Diels-alder conjugation methods | |
| HK1257776B (en) | Antibody conjugates comprising toll-like receptor agonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210422 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210422 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220419 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221115 |